American Association for Cancer Research
bcd-23-0062_supplementary_data_3_suppsd3.xlsx (18.39 MB)

Supplementary Data 3 from Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma

Download (18.39 MB)
posted on 2024-01-08, 08:20 authored by Seth J. Welsh, Benjamin G. Barwick, Erin W. Meermeier, Daniel L. Riggs, Chang-Xin Shi, Yuan Xiao Zhu, Meaghen E. Sharik, Megan T. Du, Leslie D. Abrego Rocha, Victoria M. Garbitt, Caleb K. Stein, Joachim L. Petit, Nathalie Meurice, Yuliza Tafoya Alvarado, Rodrigo Fonseca, Kennedi T. Todd, Sochilt Brown, Zachery J. Hammond, Nicklus H. Cuc, Courtney Wittenberg, Camille Herzog, Anna V. Roschke, Yulia N. Demchenko, Wei-dong D. Chen, Peng Li, Wei Liao, Warren J. Leonard, Sagar Lonial, Nizar J. Bahlis, Paola Neri, Lawrence H. Boise, Marta Chesi, P. Leif Bergsagel

Differential Accessible Regions in JJN3 and KMS11


National Cancer Institute (NCI)

United States Department of Health and Human Services

Find out more...



Multiple myeloma (MM) is a malignancy that is often driven by MYC and that is sustained by IRF4, which are upregulated by super-enhancers. IKZF1 and IKZF3 bind to super-enhancers and can be degraded using immunomodulatory imide drugs (IMiD). Successful IMiD responses downregulate MYC and IRF4; however, this fails in IMiD-resistant cells. MYC and IRF4 downregulation can also be achieved in IMiD-resistant tumors using inhibitors of BET and EP300 transcriptional coactivator proteins; however, in vivo these drugs have a narrow therapeutic window. By combining IMiDs with EP300 inhibition, we demonstrate greater downregulation of MYC and IRF4, synergistic killing of myeloma in vitro and in vivo, and an increased therapeutic window. Interestingly, this potent combination failed where MYC and IRF4 expression was maintained by high levels of the AP-1 factor BATF. Our results identify an effective drug combination and a previously unrecognized mechanism of IMiD resistance. These results highlight the dependence of MM on IKZF1-bound super-enhancers, which can be effectively targeted by a potent therapeutic combination pairing IMiD-mediated degradation of IKZF1 and IKZF3 with EP300 inhibition. They also identify AP-1 factors as an unrecognized mechanism of IMiD resistance in MM.See related article by Neri, Barwick, et al., p. 56.See related commentary by Yun and Cleveland, p. 5.This article is featured in Selected Articles from This Issue, p. 4